New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2013
16:04 EDTINFIInfinity Pharmaceuticals outlines expected 2013 development milestones
Infinity is developing a portfolio of PI3K inhibitors which includes IPI-145 and IPI-443, potent, oral inhibitors of PI3K-delta and PI3K-gamma, as well as retaspimycin hydrochloride (HCl), a potent and selective Hsp90 inhibitor. Infinity anticipates achieving the following development milestones in 2013:2013: Initiate at least two additional trials in patients with hematologic malignancies 2013: Report additional data from ongoing Phase 1 trial in patients with advanced hematologic malignancies 1H2013: Initiate a Phase 2 trial in patients with rheumatoid arthritis 2H2013: Provide update on Phase 2a trial in patients with mild, allergic asthma
News For INFI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 24, 2015
16:04 EDTINFIInfinity Pharmaceuticals reports Q4 EPS (83c), consensus (98c)
Reports Q4 revenue $4.36M, consensus $5.61M. Completion of patient enrollment in DYNAMO and DUO trials expected in 2015, topline data from DYNAMO is anticipated in the second half of 2015 and three new clinical studies of Duvelisib are expected to begin in 2015, the company said. At December 31, 2014, Infinity had total cash, cash equivalents and available-for-sale securities of $333.2M, compared to $214.5M at December 31, 2013.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use